Association of the Genetic Variation in the Long Non-Coding RNA FENDRR with the Risk of Developing Hypertrophic Cardiomyopathy.
Elías Cuesta-LlavonaRebeca LorcaValeria RolleBelén AlonsoSara IglesiasJulian Rodríguez-RegueroIsrael David Duarte-HerreraSergio Pérez-OliveiraAlejandro Junco-VicenteClaudia García LagoEliecer CotoJuan Gómez de OñaPublished in: Life (Basel, Switzerland) (2022)
Background: In around 40-60% of Hypertrophic Cardiomyopathy (HCM) cases pathogenic variants are not identified. Our aim was to evaluate the possible association of lncRNAs with the risk of developing HCM. Methods: We sequenced 10 lncRNAs coding genes that have been associated with cardiovascular disease in a discovery cohort (238 HCM patients and 212 controls) by NGS, and genotyped rs74035787 G>A and rs1424019 A>G polymorphism in a validation cohort (962 HCM patients and 923 controls). Finally, we sequenced the FENDRR promoter by Sanger sequencing. Results: We observed by NGS that FENDRR rs39527, rs39529 and rs40384 polymorphisms were significantly associated with HCM in our cohort ( p = 0.0284; OR: 0.24, 95%CI: 0.07-0.86). NGS results were confirmed by genotyping rs74035787 polymorphism ( p = 0.001; OR:0.38, 95%CI: 0.21-0.66). Moreover, it is also associated when stratification by sex ( p = 0.003; OR:0.20, 95%CI: 0.06-0.53), and age (≥50 years old p = 0.001, OR:0.33, 95%CI: 0.16-0.63) Moreover, the risk of HCM in the carriers of the GG genotype of the rs1424019 polymorphism was significantly higher than that of the AA/AG genotypes carriers in the elderly subjects ( p = 0.045, OR:1.24, 95%CI: 1.01-1.53). On the other hand, we observed significant differences in the rs74035787 A/rs1424019 G haplotype frequency ( p = 0.0035; OR: 0.20, 95%CI: 0.07-0.59). Conclusions: Our study suggested a significant association between FENDRR gene variants and HCM.